ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

AVTX vs RLMD // RSI-14 & 200D SMA MOMENTUM

Avalo Therapeutics Inc. (NASDAQ) VS. Relmada Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: AVTX 2 — RLMD 2
▲ RSI-14 & 200D SMA MOMENTUM LEADER: RLMD
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AVTX VS. RLMD) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC AVTX RLMD SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -12.90% -12.48% -0.42 RLMD /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) -65.00% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.66 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 1/9 +1.00 AVTX /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum ACTIVE 24.4 52.7 -28.30 RLMD /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $384.5M $381.9M $2.6M AVTX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR AVTX REV RLMD REV AVTX GROSS % RLMD GROSS % AVTX FCF RLMD FCF
FY 2025 $59.0K $165.5M — — -$51.5M -$45.8M
FY 2024 $441.0K $234.9M — — -$49.1M -$51.8M
FY 2023 $1.9M — — — -$30.7M —
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AVTX // BETA —
RLMD // BETA —